Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older

Cancer

Volumn 120, Issue 1, 2014, Pages 43-51

  Thomsen, Frederik B ^a   Bandak, Mikkel ^a   Thomsen, Maria F ^b   Lauritsen, Jakob ^a   Christensen, Ib J ^c   Daugaard, Gedske ^a  

^a Copenhagen University Hospital ^*  (Denmark)

^b AMAGER HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

germ cell cancer; older patients; survival; treatment intensity; treatment toxicity

Indexed keywords

BLEOMYCIN; CARBON MONOXIDE; CISPLATIN; ETOPOSIDE; HEMOGLOBIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CARBON MONOXIDE DIFFUSION CAPACITY; COMORBIDITY; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG DOSE REDUCTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LUNG FUNCTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; SURVIVAL TIME; TREATMENT RESPONSE;

GERM CELL CANCER; OLDER PATIENTS; SURVIVAL; TREATMENT INTENSITY; TREATMENT TOXICITY;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CASE-CONTROL STUDIES; CISPLATIN; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84890789662     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28374     Document Type: Article

References (27)

1. Hayes-Lattin B, Nichols CR,. Testicular cancer: a prototypic tumor of young adults. Semin Oncol. 2009; 36: 432-438.
2. Einhorn LH, Williams SD,. Combination chemotherapy with cis-dichlorodiammineplatinum(II) and Adriamycin for testicular cancer refractory to vinblastine plus bleomycin. Cancer Treat Rep. 1978; 62: 1351-1353. (Pubitemid 9031225)
3. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8: 784-796. (Pubitemid 47321601)
4. Fossa SD, Cvancarova M, Chen L, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011; 29: 963-970.
5. Spermon JR, Witjes JA, Kiemeney LA,. Difference in stage and morphology-adjusted survival between young and elderly patients with a testicular germ cell tumor. Urology. 2002; 60: 889-893. (Pubitemid 35300361)
6. Verhoeven RH, Gondos A, Janssen-Heijnen ML, et al. Testicular cancer in Europe and the USA: survival still rising among older patients. Ann Oncol. 2013; 24: 205-213.
7. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of 3 or 4 cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001; 19: 1629-1640. (Pubitemid 32230862)
8. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 3187-3205. (Pubitemid 46638957)
9. Finkelstein DM, Muzikansky A, Schoenfeld DA,. Comparing survival of a sample to that of a standard population. J Natl Cancer Inst. 2003; 95: 1434-1439. (Pubitemid 37279328)
10. Bajorin D, Katz A, Chan E, Geller N, Vogelzang N, Bosl GJ,. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol. 1988; 6: 786-792.
11. Fossa SD, Oliver RT, Stenning SP, et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer. 1997; 33: 1380-1387. (Pubitemid 27404894)
12. Sant M, Aareleid T, Artioli ME, et al. Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. Eur J Cancer. 2007; 43: 585-592. (Pubitemid 46177586)
13. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R,. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009; 45: 931-991.
14. Huyghe E, Muller A, Mieusset R, et al. Impact of diagnostic delay in testis cancer: results of a large population-based study. Eur Urol. 2007; 52: 1710-1716. (Pubitemid 350052409)
15. Sekine I, Fukuda H, Kunitoh H, Saijo N,. Cancer chemotherapy in the elderly. Jpn J Clin Oncol. 1998; 28: 463-473. (Pubitemid 128527323)
16. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A,. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003; 14: 91-96. (Pubitemid 36150265)
17. Simpson AB, Paul J, Graham J, Kaye SB,. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-1995: a review of patients with germ cell tumours. Br J Cancer. 1998; 78: 1061-1066. (Pubitemid 28463983)
18. Levi JA, Raghavan D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol. 1993; 11: 1300-1305. (Pubitemid 23199133)
19. Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D,. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995; 13: 470-476.
20. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997; 15: 1837-1843. (Pubitemid 27209512)
21. Toner GC, Stockler MR, Boyer MJ, et al. Comparison of 2 standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet. 2001; 357: 739-745. (Pubitemid 32217680)
22. Wheater MJ, Manners J, Nolan L, Simmonds PD, Hayes MC, Mead GM,. The clinical features and management of testicular germ cell tumours in patients aged 60 years and older. BJU Int. 2011; 108: 1794-1799.
23. Feldman DR, Voss MH, Jacobsen EP, et al. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013; 119: 2574-2581.
24. Carreca I, Balducci L, Extermann M,. Cancer in the older person. Cancer Treat Rev. 2005; 31: 380-402. (Pubitemid 41430692)
25. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995; 1: 33-42.
26. Proctor SJ, Rueffer JU, Angus B, et al. Hodgkin's disease in the elderly: current status and future directions. Ann Oncol. 2002; 13 (suppl 1): 133-137. (Pubitemid 34567417)
27. Brenner H, Gondos A, Pulte D,. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008; 111: 2977-2983.